The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Donepezil for vascular cognitive impairment
Abstract
BACKGROUND: Vascular disease is the second commonest cause of dementia after Alzheimer's disease. There are difficulties in classifying patients with this type of cognitive impairment owing to varied clinical presentation and different types of arterial disease. There is some degree of overlap in the neuropathology of Alzheimer's and vascular dementia. Deficient cholinergic neurotransmission, a characteristic of Alzheimer's disease, has been postulated to contribute to the cognitive impairment of vascular disease of the brain. Cholinesterase inhibitors, such as donepezil, may therefore be a rational treatment. OBJECTIVES: To assess the clinical efficacy and tolerability of donepezil on cognitive function, clinical global impression, activities of daily living and social functioning of people with vascular cognitive impairment. SEARCH STRATEGY: Relevant randomized controlled trials were identified from a search of the Cochrane Dementia and Cognitive Improvement Group Specialized Register on 21 July 2003 using the terms donepezil, E2020 and Aricept. This Register consists of records from all major healthcare databases and many ongoing trials databases. Unpublished trials were requested from the drug company Eisai Inc and they provided us with the required data. SELECTION CRITERIA: All unconfounded randomized double-blind trials comparing donepezil with placebo were eligible for inclusion. Trials using combinations of donepezil with other pharmacological interventions were excluded. DATA COLLECTION AND ANALYSIS: Both reviewers assessed studies against the criteria for inclusion and extracted data. Data were pooled where appropriate, and weighted mean differences or Peto odds ratios with 95% confidence intervals calculated. Intention-to-treat analysis was undertaken when possible. MAIN RESULTS: Two large-scale, randomized, double-blind, parallel-group controlled trials were identified for inclusion. A total of 1219 people with mild to moderate cognitive decline due to probable or possible vascular dementia (according to the NINCDS/AIREN criteria and the Hachinski Ischemia Scale) were recruited. Donepezil, at doses of 5 or 10 mg a day was compared with placebo for 24 weeks. For each outcome measure, mean change from baseline at weeks 12 and 24, using a last observation carried forward analysis, was calculated. Cognitive function: The donepezil groups showed statistically significantly better performance than the placebo groups on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) at 12 and 24 weeks. The donepezil groups produced statistically significantly better scores than the placebo groups on the Mini-Mental State Examination (MMSE) at 12 and 24 weeks. Global function: The sum of the boxes of the Clinical Dementia Rating (CDR-SB) showed at 24 weeks a statistically significant benefit of 10 mg donepezil daily over both placebo and a 5 mg daily dosage. The Clinician's Interview-Based Impression of Change-plus version (CIBIC-plus) showed improved global function of participants taking 5 mg of donepezil daily compared with the placebo group but this was not seen in the higher dose group. Activities of daily living and social behaviour: On the Instrumental Activity of Daily Living (IADL) scale, there was no statistically significant difference between the groups taking donepezil 5mg per day donepezil and placebo, but the group taking 10 mg of donepezil a day showed benefit compared with placebo There were statistically significant benefit for donepezil at either dosage compared with placebo on the Alzheimer's Disease Functional Assessment and Change Scale (ADFACS). Tolerability and adverse effects: Broad range of adverse events were reported in the studies and data confirmed that donepezil was well tolerated, and most of the side effects were transient and were resolved by stopping the medication. Some of these events, especially nausea, diarrhoea, anorexia and cramp appeared more frequently on the 10 mg dose where there was a statistically significant difference compared with placebo. Drop-out: The drop-out rate was similar between the groups, 84.2% (330) patients completed the studies. The withdrawal rate was low and due mainly to side effects. REVIEWER'S CONCLUSIONS: Evidence from the available studies support the benefit of donepezil in improving cognition function, clinical global impression and activities of daily living in patients with probable or possible mild to moderate vascular cognitive impairment after 6 months treatment. Extending studies for longer periods would be desirable to establish the efficacy of donepezil in patients with advanced stages of cognitive impairment. Moreover, there is an urgent need for establishing specific clinical diagnostic criteria and rating scales for vascular cognitive impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Chui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00305-3 · Cited by 1,139
Type 2 diabetes mellitus, cognitive impairment and dementia
Stewart, R., & Liolitsa, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00027.x · Cited by 562
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386
Research works printed but not linked: 55
- Doody, 2004, Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits, NeuroBiology of Aging, 25, 469, 10.1016/S0197-4580(04)81550-1 · doi:10.1016/s0197-4580(04)81550-1
- Geldmacher, 2002, Donepezil slows functional deterioration in patients with vascular dementia, European Journal of Neurology, 9, 35
- Pratt, 2002, Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia, Journal of the Neurological Sciences, 203-204, 57, 10.1016/S0022-510X(02)00266-6 · DOI
- Pratt RD Perdomo CA The Donepezil 307 VAD Study Group Donepezil improves cognition in patients with vascular dementia results from study 307 a 24 week randomized double blind placebo controlled trial Springfield Conference 2002 The International Symposium on Advances in Alzheimer Therapy, Geneva 2002 233
- Pratt RD Perdomo CA The Donepezil 307 and 308 VaD Study Groups Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials The 7th International Geneva Springfield Symposium on Advances in Alzheimer therapy 234
- Pratt, 2002, Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits, Annals of the New York Academy of Sciences, 977, 513, 10.1111/j.1749-6632.2002.tb04859.x · DOI
- Salloway, 2002, Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients., European Journal of Neurology, 9, 165
- Seltzer, 2004, Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities., NeuroBiology of Aging, 25, 470, 10.1016/S0197-4580(04)81551-3 · doi:10.1016/s0197-4580(04)81551-3
- Doody, 2004, Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits, NeuroBiology of Aging, 25, 469, 10.1016/S0197-4580(04)81550-1 · doi:10.1016/s0197-4580(04)81550-1
- Farlow, 2003, Efficacy of donepezil in vascular dementia, Neurology, 61, 429
- Pratt, 2002, Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia, Journal of the Neurological Sciences, 203-204, 57, 10.1016/S0022-510X(02)00266-6 · DOI
- Pratt RD Perdomo CA The Donepezil 307 and 308 VaD Study Groups Population Characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized,double-blind, placebo-controlled trials Springfield Conference 2002, The International Symposium on Advances in Alzheimer Therapy, Geneva 234
- Pratt, 2002, Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits, Annals of the New York Academy of Sciences, 977, 513, 10.1111/j.1749-6632.2002.tb04859.x · DOI
- Salloway S Pratt RD Perdomo CA The Donepezil 308 Study Group Donepezil treated patients with vascular dementia demonstrated cognitive and global benefits: results from Study 308, a 24-week randomized double-blind, placebo-controlled trial The 8th International Conference on Alzheiner's Disease and Related Disoreders, July 20-25, Stockholm, Sweden 2002 Abstract No 219
- Salloway, 2002, Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients., European Journal of Neurology, 9, 165
- Seltzer, 2004, Donepezil Provides Significant Benefits to Patients with Vascular Dementia in their Ability to Perform Everyday Activities, NeuroBiology of Aging, 25, 470, 10.1016/S0197-4580(04)81551-3 · doi:10.1016/s0197-4580(04)81551-3
- Meyer, 2002, Donepezil treatment of vascular dementia, Annals of the New York Academy of Sciences, 977, 482, 10.1111/j.1749-6632.2002.tb04854.x · DOI
- Shua-Haim, 2000, Donepezil (Aricept R) treatment of multi infarct dementia the caregivers and clinical impression, American Journal of Alzheimer's Disease, 15, 201, 10.1177/153331750001500408 · DOI
- American Psychiatric Association, 1944, Diagnostic and Statistical Manual of Mental Disorders
- Berg, 1988, Clinical dementia rating (CDR), Psychopharmacology Bulletin, 24, 637
- Bowen, 1976, Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies 6-Davis P, Malony AJF. 1976. Selective loss of central cholinergic neurons in alzheimer's disease. Lancet 1403, Brain, 99, 459, 10.1093/brain/99.3.459 · DOI · Paper page
- Brust, 1988, Vascular dementia is overdiagnosed, Achives of Neurology, 45, 799
- Crow, 1973, An analysis of the learning defict following hyoscine administration to man, British Journal of Pharmacology, 49, 322, 10.1111/j.1476-5381.1973.tb08379.x · DOI
- Dawbarn, 2001, Neurobiology of Alzheimer's disease
- Desmond, 1993, Risk factors for cerebrovascualr disease as correlates of cognitive function in a stroke free cohort, Archives of Neurology, 50, 162, 10.1001/archneur.1993.00540020040015 · DOI · Paper page
- Ebly, 1995, Cognitive impairment in the non demented elderly result from the Canadian study of health and aging, Archiver of Neurology, 52, 612, 10.1001/archneur.1995.00540300086018 · DOI · Paper page
- Folstein, 1975, Mini-mental state a practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- Gearing, 1995, The Consortium to establish a registry for Alzheimer's disease (CERAD) Part X neuropathology confirmation of the clinical diagnosis of Alzheimer's disease, Neurology, 45, 461, 10.1212/WNL.45.3.461 · DOI · Paper page
- Gottfries, 1994, The neurochemistry of vascular dementia, Dementia, 5, 163
- Graham, 1997, Prevalence and severity of cognitive impairment with and without dementia in an elderly population, Lancet, 349, 1793, 10.1016/S0140-6736(97)01007-6 · DOI · Paper page
- Hachinski, 1992, Preventable senility a call for action against the vascular dementias, Lancet, 340, 645, 10.1016/0140-6736(92)92177-H · DOI · Paper page
- Hebert, 1995, Epidemiology of vascular dementia, Neuroepidemiology, 14, 240, 10.1159/000109800 · DOI · Paper page
- Heyman, 1998, Cerebral infarction in patients with autopsy proven Alzheimer's disease CERAD part XVIII, Neurology, 51, 159, 10.1212/WNL.51.1.159 · DOI · Paper page
- Hofman, 1991, The prevalence of dementia in Europe a collaborative study of 1980-1990 findings Eurodem prevalence research group, International of Journal of Epidemiology, 20, 736, 10.1093/ije/20.3.736 · DOI · Paper page
- Jorm, 1991, Cross national comparisons of the occurrence of Alzheimer's disease and vascular dementias, European Archive of Psychaitry and Clinical neuroscience, 240, 218, 10.1007/BF02189530 · DOI
- Joynt, 1988, Vascular dementia too or too little, Archives of Neurology, 45, 801, 10.1001/archneur.1988.00520310119027 · doi:10.1001/archneur.1988.00520310119027
- Knopman, 1994, The clinician interview based impression (CIBI) a clinician's global change rating scale in Alzheimer's disease, Journal of Neurology, 44, 2315, 10.1212/WNL.44.12.2315 · DOI · Paper page
- Mann, The nucleus basalis of Meynert in multi infarct vascular dementia, Mann DMA, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi infarct vascular dementia, 71, 332
- Meyer, 1995, Procpective CT confirms differences between vascular and Alzheimer's dementia, Stroke, 269, 735, 10.1161/01.STR.26.5.735 · DOI
- Meyer, 2002, Donepezil treatment of vascular dementia, Annals of the New York Academy of Sciences, 977, 482, 10.1111/j.1749-6632.2002.tb04854.x · DOI
- Mohs, 2001, A 1 year placebo controlled preservation of function survival study of donepezil in AD patients, Neurology, 57, 481, 10.1212/WNL.57.3.481 · DOI · Paper page
- Mulrow, 1997, Cochrane Collaboration Handbook
- O'Brien, 1994, How does cerebrovascular disease cause dementia, De Mentia, 5, 133
- O'Brien, 2001, Drugs for Alzheimer's disease, British Medical Journal, 323, 123, 10.1136/bmj.323.7305.123 · DOI
- Perry, 1977, Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activites in necropsy brain tissue, Journal of Neurological Science, 34, 247, 10.1016/0022-510X(77)90073-9 · DOI · Paper page
- Rockwood, 1997, Presence and treatment of vascular risk factors in patients with vascular cognitive impairment, Archives of Neurology, 54, 33, 10.1001/archneur.1997.00550130019010 · DOI
- Rockwood, 2000, Prevalence and outcomes of vascular cognitive impairment, Neurology, 54, 447, 10.1212/WNL.54.2.447 · DOI · Paper page
- Roman, 1993, Vascular dementia diagnostic criteria for research studies, Neurology, 43, 250, 10.1212/WNL.43.2.250 · DOI · Paper page
- Rosen, 1984, A new rating scale for Alzheimer's disease, American Journal of Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356 · DOI · Paper page
- Schwarz, 1999, Milameline (CI-979/RU35926) a muscarinic receptor agonist with cognition activating properties biochemical and in vivo characterization, Journal of Pharmacol Expermental Therapy, 291, 812, 10.1016/S0022-3565(24)35171-7 · DOI
- Toghi, 1996, Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as copared with Alzheimer's type dementia, Journal of Neural Transmission, 103, 1211, 10.1007/BF01271206 · DOI · Paper page
- Ueda, 1992, Prevalence and etiology of dementia in a Japanese community, Stroke, 23, 798, 10.1161/01.STR.23.6.798 · DOI · Paper page
- World Health Organization, 1992, International Statistic Classification of Disease and Related Health Problems, 25
- Zhang, 1990, The prevalence of dementia and Alzheimer's disease in Shanghai China impact of age gender and education, Annals of Neurology, 27, 428, 10.1002/ana.410270412 · DOI · Paper page
- Zhang, 1998, Mechanism of nicotine induced relaxation in the porcine basilar artery, Journal of Pharmacology Expermental Therapy, 284, 790, 10.1016/S0022-3565(24)37261-1 · DOI
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Greenberg, S. M., Ziai, W. C., Cordonnier, C., Dowlatshahi, D., Francis, B., Goldstein, J. N., Hemphill, J. C., Johnson, R., Keigher, K. M., Mack, W. J., et al. (2022) · Stroke · doi:10.1161/str.0000000000000407 · Cited by 1,639
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Metadata
- Authors
- Malouf, R., & Birks, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2004-01-26
- Volume
- 2010
- Issue
- 1
- Pages
- CD004395-CD004395
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1726357000
- Cited by
- 170
- References
- 9
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Donepezil for vascular cognitive impairment. https://app.cochat.ai/papers/10.1002/14651858.cd004395.pub2
- The paper
- Malouf, R., & Birks, J. (2004). Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004395.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.